| Revenue growth | Full-year revenue up 2%; Q4 up 2% due to supply constraints. |
|---|---|
| Margins | EBITDA margins improved 290bps to 34% through efficiency and mix shift. |
| Demand visibility | Strong demand in vaccines (Shingrix) and respiratory; mixed for general medicine. |
| Management confidence | Balanced and optimistic regarding the pivot toward specialty and oncology segments. |
Growth
Full-year EBITDA grew 11% and PAT 10% through margin expansion. Specialty/Innovation portfolio now contributes 6% of revenue, up from 2%.
Outlook
Targeting double-digit top-line growth. Management aims for a 10% revenue contribution from the innovative 'freshness index' portfolio.
Risks
Persistent supply constraints at a key CMO impacted revenue growth by 3.5%. Muted growth in the core general medicine portfolio remains a structural drag.
Earnings Call filed with BSE, NSE: GLAXO. Summary written with AI assistance from the document.
GlaxoSmithKline Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,815.70
- Market cap
- ₹47,700 Cr
- Revenue (annual)
- ₹3,822 Cr
- Net profit (annual)
- ₹1,036 Cr
- P/E (TTM)
- 44.7×Sector 50.4×
- Promoter holding
- 75.00%+0.00% QoQ
- FII holding
- 4.79%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from GlaxoSmithKline Pharmaceuticals Ltd
All →GlaxoSmithKline Pharmaceuticals Annual General Meeting
GSK Pharma's postal ballot approved Ms. Natland as NED and Mr. Akshikar's MD re-appointment. Both resolutions cleared with over 99% shareholder support.
GlaxoSmithKline Pharmaceuticals Earnings Call Transcript: Key Takeaways
GSK India delivered resilient FY26 results with double-digit EBITDA and PAT growth, despite muted 2% revenue growth due to significant supply disruptions from a CMO fire and vaccine shipment delays.
- Call
- Guides 10% growth
GlaxoSmithKline Pharmaceuticals Earnings Call Transcript: Key Takeaways
GSK reported muted 2% revenue growth due to supply chain disruptions at a key CMO, but delivered record-high EBITDA margins of 35% through cost optimization and a shift toward high-margin specialty products.
- Call
- Guides 10% growth
GlaxoSmithKline Pharmaceuticals Investor Presentation: Key Takeaways
GSK India delivered strong Q1 FY27 standalone performance with revenue growing 15% and PAT up 24%, driven by portfolio transformation and core brand leadership.
GlaxoSmithKline Pharmaceuticals Q1 FY27 Results: Net Profit ₹237.2 Cr, Up 15.7% YoY
GlaxoSmithKline Pharmaceuticals Ltd reported revenue from operations of ₹938.4 Cr (+16.5% YoY) and net profit of ₹237.2 Cr (+15.7% YoY) for Q1 FY27.
- Key figure
- Net profit ₹237.2 Cr · +15.7% YoY
GlaxoSmithKline Pharmaceuticals Earnings Call: Key Takeaways
GSK Pharma Q4 FY26 earnings call highlighting 2% revenue growth, 34% EBITDA margins, and a shift toward an innovation-led specialty portfolio.